India's Venus gets OK to export to Australia; FDA hires former Genzyme senior VP;

> Indian drugmaker Venus Remedies had four plants approved by Australian regulators, paving the way for it to export products to that country. Story

> A Department of Health and Human Services report questions whether the FDA's postmarketing safety methods, Risk Evaluation and Mitigation Strategies (REMS), are effective at ensuring product safety. Article

> U.S. drug wholesaler Cardinal Health ($CAH) will spend $2 billion to buy AssuraMed, a privately held direct-to-home medical supply distributor. Story

> The FDA has named former Genzyme Senior Vice President Richard Moscicki as deputy director of a new section called science operations in its Center for Drug Evaluation and Research (CDER). Article

And Finally... The FDA has sent warning letters to the operators of 9 websites, including one with a University of Berkeley identifier, saying they all have been offering unapproved products that claim to treat influenza. Letters